Axonics (AXNX)
(Delayed Data from NSDQ)
$66.90 USD
-0.05 (-0.07%)
Updated Apr 22, 2024 11:56 AM ET
After-Market: $66.79 -0.11 (-0.16%) 7:58 PM ET
2-Buy of 5 2
D Value A Growth D Momentum C VGM
Axonics Modulation Technologies (AXNX) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$70.91 | $75.00 | $63.00 | 5.91% |
Price Target
Based on short-term price targets offered by 11 analysts, the average price target for Axonics Modulation Technologies comes to $70.91. The forecasts range from a low of $63.00 to a high of $75.00. The average price target represents an increase of 5.91% from the last closing price of $66.95.
Analyst Price Targets (11)
Broker Rating
Axonics Modulation Technologies currently has an average brokerage recommendation (ABR) of 2.46 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 13 brokerage firms. The current ABR compares to an ABR of 2.46 a month ago based on 13 recommendations.
Of the 13 recommendations deriving the current ABR, three are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 23.08% and 7.69% of all recommendations. A month ago, Strong Buy made up 23.08%, while Buy represented 7.69%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 3 | 3 | 3 | 3 | 3 |
Buy | 1 | 1 | 1 | 2 | 2 |
Hold | 9 | 9 | 9 | 8 | 8 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 2.46 | 2.46 | 2.46 | 2.35 | 2.35 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
3/4/2024 | Mizuho SecuritiesUSA | Anthony Petrone | Strong Buy | Strong Buy |
1/17/2024 | Needham & Company | Michael Matson | Moderate Buy | Hold |
1/17/2024 | Truist Securities | Richard Newitter | Hold | Hold |
1/12/2024 | Piper Sandler | Adam C Maeder | Strong Buy | Hold |
1/12/2024 | SVB Securities | Michael Kratky | Hold | Hold |
1/12/2024 | C.L. King & Associates | Kristen M Stewart | Moderate Buy | Hold |
7/28/2023 | Robert W. Baird & Co. | David Rescott | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.46 |
ABR (Last week) | 2.46 |
# of Recs in ABR | 13 |
Average Target Price | $70.91 |
LT Growth Rate | NA |
Industry | Medical Info Systems |
Industry Rank by ABR | 148 of 252 |
Current Quarter EPS Est: | -0.05 |